Abstract
Knowledge about the postintervention psychosocial status of myasthenia gravis (MG) is limited and based on questionnaire studies. In this study, the effects of improvement in muscle strength with plasmapheresis treatment on both quality of life (QoL) and psychological status of MG patients were studied. Between January 2008 and December 2009, 29 MG patients were enrolled to receive one course of plasmapheresis treatment. Differences in baseline and posttherapy clinical, laboratory, and psychosocial measures were determined. The mean MG score decreased from 7.8 points at baseline to 4.2 after plasmapheresis, accompanied by the mean antibody clearance of 56%. Psychosocial tests showed significant pre- and posttherapy differences in illness identity (mean scores 23.62 and 20.79 points, respectively) and disability (mean scores 11.28 and 7.63 points, respectively) (p < 0.01). No significant differences were found for the other indices. Although both anxiety and depression scores did not differ significantly, there was a clear change in patients, as evidenced by their decreases in severity after treatment. The mean mental components scores of QoL were still less than 40 after treatment, indicating that myasthenic patients need assistance in adapting to their disease. Thus, although plasmapheresis treatment achieved immediate improvement of myasthenic symptoms, reduced disability, and better illness identity, both emotional status and QoL did not differ significantly after intervention. Systematical evaluation for patients’ illness perceptions and emotional problems are warranted and related strategies should be taken for long-term stabilization of psychosocial function.
Similar content being viewed by others
References
Burns TM, Conaway MR, Cutter GR, Sanders DB (2008) Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. Muscle Nerve 38:957–963
Busch C, Machens A, Pichlmeier U (1996) Long-term outcomes and quality of life after thymectomy for myasthenia gravis. Ann Surg 2:225–232
Chaudhuri A, Behan PO (2009) Myasthenic crisis. QJ Med 102:97–107
Chen YT, Tsay SL, Lin PF (2003) The relationships between illness perception, mood and quality of life in myasthenia gravis patients. J Nurs 50:43–50 (in Chinese)
Doering S, Henze T, Schüssler G (1993) Coping with myasthenia gravis and implications for psychotherapy. Arch Neurol 50:617–620
García-Carrasco M, Escárcega RO, Fuentes-Alexandro S, Riebeling C, Cervera R (2007) Therapeutic options in autoimmune myasthenia gravis. Autoimmun Rev 6:373–378
Jønsson A, Dock J, Ravnborg MH (1996) Quality of life as a measure of rehabilitation outcome in patients with multiple sclerosis. Acta Neurol Scand 93:229–235
Klauer T, Schneider W, Zettl UK (2007) Coping with neuroimmunological diseases. J Neurol 254(Suppl 2):II107–II111
Lankhorst GJ, Jelles F, Smits RC, Polman CH, Kuik DJ, Pfennings LE, Cohen L, van der Ploeg HM, Ketelaer P, Vleugels L (1996) Quality of life in multiple sclerosis: the disability and impact profile. J Neurol 243:469–674
Lundeen J, Fisher J, Kothari MJ (2004) Frequency of anxiety in myasthenia gravis. J Clin Neuromuscul Dis 6:9–12
Maniaol AH, Brunborg C, Tallaksen CME (2010) Development and validation of a self-administered questionnaire for myasthenia gravis patients. Neuroepidemiology 34:253–261
Murphy N, Confavreux C, Haas J, Konig N, Roullet E, Sailer M, Young C, Merot JL (1998) Quality of life in multiple sclerosis in France, Germany, and United Kingdom. J Neurol Neurosurg Psychiatry 65:460–466
Padua L, Evoli A, Aprile I, Caliandro P, Mazza S, Padua R, Tonali P (2001) Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements. Neurol Sci 22:363–369
Paul RH, Cohen RA, Goldstein JM, Gilchrist JM (2000) Fatigue and its impact on patients with myasthenia gravis. Muscle Nerve 23:1402–1406
Paul RH, Cohen RD, Goldstein JM, Gilchrist JM (2000) Severity of mood, self-evaluation, and vegetative symptoms of depression in myasthenia gravis. Neuropsychiatry Clin Neurosci 12:499–501
Paul RH, Nash JM, Cohen RA, Gilchrist JM, Goldstein JM (2001) Quality of life and well-being of patients with myasthenia gravis. Muscle Nerve 24:512–515
Phillip LH II, Torner JC (1996) Epidemiologic evidence for a changing natural history of myasthenia gravis. Neurology 47:1233–1238
Pinching AJ, Peters DK, Newsom-Davis J (1976) Remission of myasthenia gravis following plasma-exchange. Lancet II:1373–1376
Sanders DB, Hart IK, Mantegazza R et al (2008) An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 71:400–406
Sitek EJ, Bilińska MM, Wieczorek D, Nyka WM (2009) Neuropsychological assessment in myasthenia gravis. Neurol Sci 30:9–14
Thomas CE, Mayer SA, Gungor Y et al (1997) Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 48:1253–1260
Van der Schaaf IC, Brilstra EH, Rinkel GJE, Bossuyt PM, van Gijn J (2002) Quality of life, anxiety, and depression in patients with an intracranial aneurysm or arterio-venous malformation. Stroke 33:440–443
Wolinsky FD, Stump TE (1996) A measurement model of the Medical Outcomes Study 36-Item Short-Form Health Survey in a clinical sample of disadvantaged, older, black, and white men and women. Med Care 34:537–548
Yeh JH, Chen WH, Chiu HC (2001) Double filtration plasmapheresis in the treatment of myasthenic crisis–analysis of prognostic factors and efficacy. Acta Neurol Scand 104:78–82
Yeh JH, Chiu HC (1999) Double filtration plasmapheresis in myasthenia gravis-analysis of clinical efficacy and prognostic parameters. Acta Neurol Scand 100:305–309
Acknowledgments
This work was supported, in part, by research grants (SKH-8302-97-DR-17) from the Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chen, YT., Chang, Y., Chiu, HC. et al. Psychosocial aspects in myasthenic patients treated by plasmapheresis. J Neurol 258, 1240–1246 (2011). https://doi.org/10.1007/s00415-011-5913-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-011-5913-4